Chai Discovery Inks License Agreement With Pfizer To Deploy Its AI Platform As Part Of Drug Discovery Engine
Benzinga · 6h ago
Share
Listen to the news
Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.
The agreement will enable Pfizer to deploy Chai's AI platform as part of its drug discovery engine, gaining early access to the Chai-3 model as well as a custom model that leverages Pfizer's proprietary data and is tailored to Pfizer's workflows.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved